凯因科技(688687.SH)：撤回药品注册申请

Core Viewpoint - The company, Kaiyin Technology (688687.SH), has received approval from the National Medical Products Administration to withdraw its drug registration application for the interferon α-2 injection with a new indication for hepatitis B [1] Group 1 - The company has decided to withdraw the drug registration application for the interferon α-2 injection, which was intended for a new indication related to hepatitis B [1] - The new indication proposed was for the use of Paiyisheng® in combination with Tenofovir Alafenamide (TAF) for the treatment of adult chronic hepatitis B (HBV) patients [1]